This website uses cookies. By using our website you consent to all cookies in accordance with our Cookie Policy.
AcceptZeus Capital acted as nominated adviser (NOMAD) and sole broker to Oncimmune Holdings plc (Ticker: ONC.L) on its AIM IPO and £11m fundraising, resulting in a market capitalisation on admission of £66m
Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
Oncimmune is an established company with a pioneering approach to cancer detection. Its methodology has been extensively validated , and over 140,000 of its EarlyCDT-Lung tests have already been sold in the USA. The tests are now part of the 12,000-person ECLS Study being run in collaboration with NHS Scotland in Tayside and Greater Glasgow. This is the largest lung cancer screening trial ever conducted.
Oncimmune was originally spun-out from University of Nottingham in 2002 with facilities in the UK and USA. The funds raised will be used to accelerate the commercial development of the business and to develop early detection tests for Liver and Ovarian cancers.
Surface Transforms
Date: 29 Jan 2021
Sector: Automobiles & Parts
Type: Fundraise
Value: £20m
Sumo Group plc
Date: 21 Jul 2020
Sector: Leisure
Type: Fundraise
Value: £13.7m
boohoo Group plc
Date: 15 May 2020
Sector: General Retailers
Type: Fundraise
Value: £198m
Xafinity plc
Date: 11 Jan 2018
Sector: Financial Services
Type: Fundraise
Value: £70m
Mkt Cap Admission: £386m
Public Markets
We provide advice to listed and non-listed companies looking to raise capital on public markets.